Evidence of hypertriglyceridemia in managing HIV patients on efavirenz.
Of the recently approved antiretroviral agents, efavirenz has become a popular medication for the treatment of HIV infection. The efficacy of an efavirenz-based regimen has allowed the use of a combination of this medication with other antiretroviral agents in all levels of HIV disease, resulting in decreased viral replication and positive clinical results. Efavirenz is also proposed as an acceptable agent to switch to from a protease inhibitor-based regimen to reduce the risk of metabolic complications. In addition, the favorable side-effect profile, diminished pill burden for clients, and daily dosing have contributed to its popularity. Primary care practitioners should be cognizant of the possible side-effect profile of antiretroviral therapy combinations and enter into a collaborative relationship with the infectious disease clinician to ensure safe and effective patient care.
Savini
C J
CJ
HIV Wellness Clinic, Christiana Care Health System, Georgetown, Delaware, USA.
James
C W
CW
Miller
J L
JL
Wilson
S A
SA
Cohen
D M
DM
Perlada
D E
DE
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D003691:Delaware / Q000453:epidemiology; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000451:nursing; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology*; D008297:Male; D008499:Medical Records; D010078:Oxazines / Q000009:adverse effects*; D012189:Retrospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D014280:Triglycerides / Q000097:blood
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D014280:Triglycerides; C098320:efavirenz